Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Alagille syndrome

    - PMLiVE

    Ipsen to acquire ImCheck Therapeutics in a deal worth up to €1bn

    The acquisition includes a clinical stage acute myeloid leukaemia treatment currently in phase 1/2 trials

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    Ipsen’s tumour treatment receives MHRA marketing authorisation

    This is the first approval in the UK for previously treated advanced neuroendocrine tumours

    - PMLiVE

    Ipsen receives EC approval for Cabometyx in advanced neuroendocrine tumours

    Treatment options following disease progression have previously been limited for many patients

    - PMLiVE

    Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma

    The drug is already approved in the EU across three other multiple myeloma indications

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma

    More than 50,000 cases of the blood cancer are diagnosed in Europe each year

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Roche’s Itovebi granted EC approval to treat advanced breast cancer patients

    Hormone receptor-positive breast cancer accounts for around 70% of all breast cancer cases

    EU flag

    EC approves SpringWorks Therapeutics’ Ezmekly to treat rare genetic disorder NF1

    Neurofibromatosis type 1 affects an estimated 135,000 people in the EU

    EU flag

    EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

    The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

    EU flag

    EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

    An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links